Report Detail

Pharmaceuticals & Healthcare Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2019

  • RnM3868729
  • |
  • 18 March, 2020
  • |
  • Global
  • |
  • 37 Pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Proliferative Vitreoretinopathy (PVR) - Overview

              Proliferative Vitreoretinopathy (PVR) - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development

                                      Aldeyra Therapeutics Inc

                                        Aptitude Medical Systems Inc

                                          F. Hoffmann-La Roche Ltd

                                            Focal Point Pharmaceuticals Inc

                                              Novartis AG

                                                Proliferative Vitreoretinopathy (PVR) - Drug Profiles

                                                  Aptamers to Inhibit PDGF for Proliferative Vitreoretinopathy - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          methotrexate - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  OM-101 - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          PRM-167 - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          XOMA-089 - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  Proliferative Vitreoretinopathy (PVR) - Dormant Projects

                                                                                                    Proliferative Vitreoretinopathy (PVR) - Product Development Milestones

                                                                                                      Featured News & Press Releases

                                                                                                        Feb 24, 2020: Aldeyra Therapeutics provides update on its proliferative vitreoretinopathy drug candidate at 2020 Research & Development Day

                                                                                                          Dec 20, 2019: Aldeyra Therapeutics enrols first patient in Phase III GUARD study

                                                                                                            Sep 24, 2019: Aldeyra Therapeutics receives Fast Track Designation for ADX-2191 for the prevention of Proliferative Vitreoretinopathy

                                                                                                              May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting

                                                                                                                May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting

                                                                                                                  Appendix

                                                                                                                    Methodology

                                                                                                                      Coverage

                                                                                                                        Secondary Research

                                                                                                                          Primary Research

                                                                                                                            Expert Panel Validation

                                                                                                                              Contact Us

                                                                                                                                Disclaimer

                                                                                                                                Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020

                                                                                                                                Summary

                                                                                                                                Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

                                                                                                                                Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes.

                                                                                                                                Report Highlights

                                                                                                                                Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

                                                                                                                                Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                Scope

                                                                                                                                - The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
                                                                                                                                - The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                - The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics and enlists all their major and minor projects.
                                                                                                                                - The pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                - The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology)

                                                                                                                                Reasons to buy

                                                                                                                                - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                - Find and recognize significant and varied types of therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
                                                                                                                                - Classify potential new clients or partners in the target demographic.
                                                                                                                                - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                - Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
                                                                                                                                - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


                                                                                                                                Summary:
                                                                                                                                Get latest Market Research Reports on Proliferative Vitreoretinopathy (PVR). Industry analysis & Market Report on Proliferative Vitreoretinopathy (PVR) is a syndicated market report, published as Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Proliferative Vitreoretinopathy (PVR) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                Last updated on

                                                                                                                                REPORT YOU MIGHT BE INTERESTED

                                                                                                                                Purchase this Report

                                                                                                                                $2,000.00
                                                                                                                                $4,000.00
                                                                                                                                $6,000.00
                                                                                                                                1,499.22
                                                                                                                                2,998.44
                                                                                                                                4,497.66
                                                                                                                                1,684.69
                                                                                                                                3,369.37
                                                                                                                                5,054.06
                                                                                                                                208,934.00
                                                                                                                                417,868.00
                                                                                                                                626,802.00
                                                                                                                                148,131.20
                                                                                                                                296,262.40
                                                                                                                                444,393.60
                                                                                                                                Credit card Logo

                                                                                                                                Related Reports


                                                                                                                                Reason to Buy

                                                                                                                                Request for Sample of this report